COVID-19 Current Affairs - 2020
DRDO develops 1000 Bed Hospital for Treatment of COVID-19 patients in 12 Days, Wards Named after Indian Army Soldiers
Defence Research and Development Organisation (DRDO) has established a 1000 bed facility in 12 days adjacent to the office of Controller General of Defence Accounts (CGDA) on Ulan Bator Road near Domestic Terminal of Indira Gandhi International Airport.
The facility will be providing treatment and care for the COVID-19 positive patients. On 5th July 2020, Rajnath Singh (Union Defence Minister) Dr Harsh Vardhan (Union Minister of Health and Family Welfare) and Amit Shah (Union Home Minister) visited the facility for reviewing the preparedness.
The facility is named Sardar Vallabhbhai Patel COVID-19 Hospital.
About the Facility
Along with Tata Sons Private Limited, Sardar Vallabhbhai Patel COVID-19 Hospital is developed by DRDO. The facility is set up in the land belonging to the Indian Air Force. The facility is set up at about 25,000 square metres of land and will have separate blocks for patients and healthcare workers. Apart from this a testing laboratory and a pharmacy have also been set up in the facility.
Team of doctors, nurses, healthcare staff and other support staff at the facility will be from Armed Forces Medical Services.
The facility has a total of 1000 beds for patients out of which 250 are Intensive Care Unit (ICU) beds.
Wards named after Indian Army Soldiers
The wards at the Sardar Vallabhbhai Patel COVID-19 Hospital are named after the Indian Army Soldiers who have lost their lives on 15th June 2020 during the violent clash at Galwan Valley with the Chinese.
Intensive Care Unit (ICU) and the ventilator ward is named after Indian Armed Forces Commissioned Officer Colonel Bikkumalla Santosh Babu.
Tags: Amit Shah • COVID-19 • Defence Minister Rajnath Singh • Defence Research and Development Organisation (DRDO) • Dr Harsh Vardhan
On 2nd July 2020, the Drug Controller General of India (DCGI) has given approval for human clinical trials to Ahmedabad based Cadila Healthcare Limited (Zydus Healthcare). The permission is for the Phase-I and Phase-II clinical trials of the vaccine.
Zydus Healthcare’s COVID-19 vaccine become the 2nd Indigenously developed vaccine to get the permission of the DCGI for human clinical trials after Bharat Biotech’s COVAXIN. The human clinical trials for the vaccine are expected to be completed in three months as per media reports.
Success during Clinical Trials on Animals
The approval for the human clinical trials was given by the DCGI based on the recommendation made by the COVID-19 Subject Expert Committee. The Subject Expert Committee recommendation was on the basis of the data provided to the DCGI by Zydus Healthcare on the success of their COVID-19 vaccine during clinical trials on the animals.
With respect to safety and immunogenicity, the potential novel coronavirus vaccine developed by the Zydus Healthcare was found to be successful during animal studies, this was informed by the Drug Controller General of India Dr. V.G. Somani.
Headquartered in Gujarat’s Ahmedabad, Zydus Healthcare is one of the leading manufacturers of generic drugs in India. It was founded in the year 1952 by Ramanbhai Patel. The company is also known as Cadila Healthcare Limited or Zydus Cadila Healthcare Limited.